Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven C Katz

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Annals of Surgery|March 21, 2009
Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinomaSteven C Katz, Jinru Shia, Kui Hin Liau, et al.
Cancer Gene Therapy|June 13, 2022
Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibitionChandra C Ghosh, Kara R Heatherton, Kyle P O' Connell, et al.
Surgery|June 30, 2023
Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer modelBenedict A Capacio, Jayanth S Shankara Narayanan, Diego A Vicente, et al.
Journal of Translational Medicine|February 26, 2013
Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumorSteven C Katz, Rachel A Burga, Seema Naheed, et al.
Frontiers in Oncology|October 22, 2025
Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor modelsLauren Cournoyer, Yujia Liu, David B Jaroch, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2011
Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosisSteven C Katz, Kristin Ryan, Naseem Ahmed, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2015
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-TRachel A Burga, Mitchell Thorn, Gary R Point, et al.
Vaccines|August 28, 2021
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor ActivityLouis F Chai, John C Hardaway, Kara R Heatherton, et al.
Surgery|July 5, 2020
Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse modelJayanth S Shankara Narayanan, Diego A Vicente, Partha Ray, et al.
Annals of Surgical Oncology|February 19, 2017
Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better OutcomeMichael J Cavnar, Simon Turcotte, Steven C Katz, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Annals of Surgery|March 21, 2009
Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinomaSteven C Katz, Jinru Shia, Kui Hin Liau, et al.
Cancer Gene Therapy|June 13, 2022
Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibitionChandra C Ghosh, Kara R Heatherton, Kyle P O' Connell, et al.
Surgery|June 30, 2023
Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer modelBenedict A Capacio, Jayanth S Shankara Narayanan, Diego A Vicente, et al.
Journal of Translational Medicine|February 26, 2013
Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumorSteven C Katz, Rachel A Burga, Seema Naheed, et al.
Frontiers in Oncology|October 22, 2025
Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor modelsLauren Cournoyer, Yujia Liu, David B Jaroch, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2011
Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosisSteven C Katz, Kristin Ryan, Naseem Ahmed, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2015
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-TRachel A Burga, Mitchell Thorn, Gary R Point, et al.
Vaccines|August 28, 2021
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor ActivityLouis F Chai, John C Hardaway, Kara R Heatherton, et al.
Surgery|July 5, 2020
Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse modelJayanth S Shankara Narayanan, Diego A Vicente, Partha Ray, et al.
Annals of Surgical Oncology|February 19, 2017
Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better OutcomeMichael J Cavnar, Simon Turcotte, Steven C Katz, et al.
Pageof 8